TOP-217 A Randomized, Placebo-Controlled Phase Ib/IIa Trial to Evaluate the Safety, Tolerability, and Efficacy of BGT-002, an Adenosine Triphosphate Citrate Lyase Inhibitor in Patients with NAFLD: Interim Analysis